Evidence map›Paper›PMID 41503151›Full record

ArticleJBMR plus2026

Denosumab treatment of osteoporotic women arrests cortical bone remodeling events at the reversal-resorption phase but does not affect ongoing bone formation.

Xenia Goldberg Dahl, Jean-Paul Roux, Jean-Marie Delaisse, Shuang Huang, Pascale Chavassieux, Christina M Andreasen, Thomas L Andersen

Abstract read
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xenia Goldberg DahlMolecular Bone Histology Team, Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.ORCID https://orcid.org/0000-0002-4922-2478
Jean-Paul RouxUniv Lyon, INSERM, UMR 1033, UFR de Médecine Lyon-Est, F-69008 Lyon, France.
Jean-Marie DelaisseMolecular Bone Histology Team, Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.
Shuang HuangCenter for Design and Analysis, Amgen Inc., Thousand Oaks, CA 91320, United States.
Pascale ChavassieuxUniv Lyon, INSERM, UMR 1033, UFR de Médecine Lyon-Est, F-69008 Lyon, France.ORCID https://orcid.org/0000-0001-5128-7361
Christina M AndreasenMolecular Bone Histology Team, Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.ORCID https://orcid.org/0000-0002-2624-5677
Thomas L AndersenMolecular Bone Histology Team, Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, 5230 Odense M, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab is an anti-resorptive therapy that effectively reduces fracture risk and increases BMD in women with postmenopausal osteoporosis. In this study, we focused on the less well-investigated cortical remodeling process and its transition from erosion to formation after denosumab treatment, using a histomorphometric classification of intracortical pores. Cortical bone is more prominent in non-vertebral bones, where denosumab is less effective in fracture reduction. In iliac crest biopsies from the FREEDOM-study, where postmenopausal osteoporotic women were treated with placebo (

Indexed as

antiresorptivesbone modeling and remodelingosteoblastsosteoclastsosteoporosis

Identifiers

PMID41503151
PMCPMC12771366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.